Turning Point Therapeutics, Inc.
|Number of Estimates|
Turning Point Therapeutics, Inc. engages in the discovery and development of precision medicines for cancer and other diseases. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by J. Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA.
Market Cap: 1.48 Billion
Primary Exchange: NASDAQ
Shares Outstanding: 35.9 Million
Float: 29.2 Million
Sector: Health Technology
Industry: Pharmaceuticals: Major
Longest drawdown: 82 trading days
From: 2019-08-29 To: 2019-12-13
|Ex-Date||Payment Date||Record Date||Declared Date||Amount||Flag||Dividend Type||Qualified||Indicated|
|Ex-Date||Declared Date||Record Date||Payment Date||Ratio||To Factor||For Factor|